Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin.
10.4166/kjg.2010.55.5.340
- Author:
Sul PARK
1
;
Jae Jin JUNG
;
Goeng Bae KIM
;
Hyung Sik YOON
;
Sang Hun KO
;
Jae Ee KO
;
Yeun Seun LEE
Author Information
1. Department of Internal Medicine, Sun General Hospital, Daejeon, Korea. cnu4169@hanmail.net
- Publication Type:Case Report ; English Abstract
- Keywords:
Oxaliplatin;
Colon cancer;
Interstitial lung diseases
- MeSH:
Aged;
Antineoplastic Agents/*adverse effects/therapeutic use;
Antineoplastic Combined Chemotherapy Protocols;
Colorectal Neoplasms/drug therapy;
Fluorouracil/*adverse effects/therapeutic use;
Humans;
Leucovorin/*adverse effects/therapeutic use;
Lung Diseases, Interstitial/chemically induced/*etiology/radiography;
Male;
Organoplatinum Compounds/*adverse effects/therapeutic use
- From:The Korean Journal of Gastroenterology
2010;55(5):340-343
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Oxaliplatin with 5-fluorouracil plus leucovorin (FOLFOX) has become the standard treatment in patients with colorectal cancer. Among known toxicities induced by oxaliplatin, hematological, gastrointestinal and neurological toxicities are common. However, acute pulmonary toxicity associated with oxaliplatin is unusual. One case of interstitial lung disease associated with the FOLFOX protocol is reported here.
